Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know On-Demand Webinar Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know Access our on-demand webinar to explore the key differences between eCTD 4.0 and eCTD 3.2.2.…CertaraAugust 11, 2025
Certara Reports Second Quarter 2025 Financial Results Press Release Certara Reports Second Quarter 2025 Financial Results RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…CertaraAugust 6, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development Blog Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…CertaraAugust 6, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator On-Demand Webinar De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…CertaraAugust 5, 2025
Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches On-Demand Webinar Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches CertaraAugust 1, 2025
Machine Learning (ML) in healthcare Blog Machine Learning (ML) in healthcare Learn about 3 distinct examples of machine learning (ML) in healthcare that utilize different techniques…CertaraAugust 1, 2025
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials Blog Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…CertaraJuly 31, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development Case Study Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.CertaraJuly 29, 2025
Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling On-Demand Webinar Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling CertaraJuly 29, 2025
MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines On-Demand Webinar MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines Learn how clinical pharmacologists and modeling experts collaborate to improve preclinical-to-clinical translation.CertaraJuly 29, 2025